• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Broadly protective influenza vaccines: design and production platforms

tetano

Editor, Senior Moderator
Curr Opin Virol. 2018 Nov 26;34:1-9. doi: 10.1016/j.coviro.2018.11.005. [Epub ahead of print]
[h=1]Broadly protective influenza vaccines: design and production platforms.[/h] Elbahesh H[SUP]1[/SUP], Saletti G[SUP]1[/SUP], Gerlach T[SUP]1[/SUP], Rimmelzwaan GF[SUP]2[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Effective vaccines are the cornerstone of our defenses against acute influenza virus infections that result in ∼500 000 annual deaths worldwide. For decades, an on-going concerted effort has been to develop a universal influenza vaccine to combat the looming threat of potentially pandemic emerging and re-emerging influenza viruses. To address the need for rapid efficacious vaccines that could mitigate the impact of seasonal and future pandemics, multiple platforms are under development and/or investigation. What is clear is that any universal vaccine must provide long-lasting cross-protective immunity that can induce both B and T cell responses. This review will explore some of the universal influenza vaccine platforms in the contexts of their ability to induce long-lasting and cross-protective T cell immunity.


PMID: 30497050 DOI: 10.1016/j.coviro.2018.11.005
 
Back
Top Bottom